AP2585A - Macrocyclic inhibitors of hepatitis C virus - Google Patents

Macrocyclic inhibitors of hepatitis C virus

Info

Publication number: AP2585A
Authority: AP; ARIPO
Prior art keywords: hepatitis; virus; macrocyclic inhibitors; macrocyclic; inhibitors
Prior art date: 2005-07-29

Application number

AP2008004306A

Other languages

English (en)

Inventor

Pierre Jean-Marie Bernard Raboisson

Herman Augustinus De Kock

Lili Hu

Original Assignee

Tibotec Pharm Ltd

Medivir Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-07-29

Filing date

2006-07-28

Publication date

2013-02-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37708968&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2585(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-07-28 Application filed by Tibotec Pharm Ltd, Medivir Ab filed Critical Tibotec Pharm Ltd

2013-02-04 Application granted granted Critical

2013-02-04 Publication of AP2585A publication Critical patent/AP2585A/xx

Links

241000711549 Hepacivirus C Species 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
- C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Plural Heterocyclic Compounds (AREA)

AP2008004306A 2005-07-29 2006-07-28 Macrocyclic inhibitors of hepatitis C virus AP2585A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP05107057		2005-07-29
EP06113097		2006-04-25

Publications (1)

Publication Number	Publication Date
AP2585A true AP2585A (en)	2013-02-04

Family

ID=37708968

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2008004306A AP2585A (en)	2005-07-29	2006-07-28	Macrocyclic inhibitors of hepatitis C virus

Country Status (31)

Country	Link
US (1)	US7659245B2 (fr)
EP (1)	EP1912981B1 (fr)
JP (1)	JP5230418B2 (fr)
KR (1)	KR101083631B1 (fr)
AP (1)	AP2585A (fr)
AR (1)	AR057702A1 (fr)
AT (1)	ATE455775T1 (fr)
AU (1)	AU2006274866B2 (fr)
BR (1)	BRPI0614153A2 (fr)
CA (1)	CA2617103C (fr)
CY (1)	CY1110008T1 (fr)
DE (1)	DE602006011905D1 (fr)
DK (1)	DK1912981T3 (fr)
EA (1)	EA014188B1 (fr)
ES (1)	ES2339702T3 (fr)
GT (1)	GT200600343A (fr)
HR (1)	HRP20100209T1 (fr)
IL (1)	IL188320A (fr)
ME (1)	ME01454B (fr)
MY (1)	MY151026A (fr)
NO (1)	NO20081075L (fr)
NZ (1)	NZ564540A (fr)
PE (1)	PE20070343A1 (fr)
PL (1)	PL1912981T3 (fr)
PT (1)	PT1912981E (fr)
RS (1)	RS51227B (fr)
SI (1)	SI1912981T1 (fr)
SV (1)	SV2008002641A (fr)
TW (1)	TWI387597B (fr)
UY (1)	UY29704A1 (fr)
WO (1)	WO2007014927A2 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY140680A (en)	2002-05-20	2010-01-15	Bristol Myers Squibb Co	Hepatitis c virus inhibitors
BRPI0506948B1 (pt)	2004-01-30	2018-09-18	Medivir Ab	inibidores de serina protease ns-3 de hcv
PE20070211A1 (es)	2005-07-29	2007-05-12	Medivir Ab	Compuestos macrociclicos como inhibidores del virus de hepatitis c
RU2436787C2 (ru)	2005-07-29	2011-12-20	Тиботек Фармасьютикалз Лтд.	Макроциклические ингибиторы вируса гепатита с
JO2768B1 (en) *	2005-07-29	2014-03-15	تيبوتيك فارماسيوتيكالز ليمتد	Large cyclic inhibitors of hepatitis C virus
WO2007014925A1 (fr)	2005-07-29	2007-02-08	Tibotec Pharmaceuticals Ltd.	Inhibiteurs macrocycliques du virus de l'hépatite c
BRPI0617274A2 (pt)	2005-10-11	2011-07-19	Intermune Inc	compostos e métodos para a inibição de replicação viral de hepatite c
US7741281B2 (en)	2005-11-03	2010-06-22	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
RU2008152171A (ru)	2006-07-05	2010-08-10	Интермьюн, Инк. (Us)	Новые ингибиторы вирусной репликации гепатита с
US7935670B2 (en)	2006-07-11	2011-05-03	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
DK2041156T3 (en)	2006-07-13	2014-02-24	Achillion Pharmaceuticals Inc	4-AMINO-4-OXOBUTANOYL Peptides AS INHIBITORS OF VIRUS REPLICATION
US8343477B2 (en)	2006-11-01	2013-01-01	Bristol-Myers Squibb Company	Inhibitors of hepatitis C virus
US7772180B2 (en)	2006-11-09	2010-08-10	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7763584B2 (en)	2006-11-16	2010-07-27	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8003604B2 (en)	2006-11-16	2011-08-23	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7888464B2 (en)	2006-11-16	2011-02-15	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
ES2470568T3 (es) *	2006-11-17	2014-06-24	Janssen R&D Ireland	Inhibidores macroc�clicos del virus de la hepatitis C
BRPI0806853B1 (pt) *	2007-02-01	2018-03-20	Janssen Sciences Ireland Uc	Processos e intermediários para preparar um inibidor de protease macrocíclico de hcv
BRPI0807087A2 (pt) *	2007-02-08	2014-06-10	Tibotec Pharm Ltd	Inibidores de hcv macrocíclicos substituídos de pirimidina
ITMI20071616A1 (it)	2007-08-03	2009-02-04	Cosmo Spa	Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.
WO2009042668A2 (fr) *	2007-09-24	2009-04-02	Achillion Pharmaceuticals, Inc.	Peptides contenant de l'urée en tant qu'inhibiteurs de la réplication virale
US8383583B2 (en)	2007-10-26	2013-02-26	Enanta Pharmaceuticals, Inc.	Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
US8426360B2 (en) *	2007-11-13	2013-04-23	Enanta Pharmaceuticals, Inc.	Carbocyclic oxime hepatitis C virus serine protease inhibitors
US8263549B2 (en)	2007-11-29	2012-09-11	Enanta Pharmaceuticals, Inc.	C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors
US8202996B2 (en)	2007-12-21	2012-06-19	Bristol-Myers Squibb Company	Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
EP2226315A4 (fr)	2007-12-28	2012-01-25	Carna Biosciences Inc	Dérivé de 2-aminoquinazoline
CA2719008A1 (fr)	2008-03-20	2009-09-24	Enanta Pharmaceuticals, Inc.	Composes macrocycliques fluores en tant qu'inhibiteurs du virus de l'hepatite c
US8163921B2 (en)	2008-04-16	2012-04-24	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
EP2300491B1 (fr)	2008-05-29	2016-01-06	Bristol-Myers Squibb Company	Inhibiteurs du virus de l hépatite c
US7964560B2 (en)	2008-05-29	2011-06-21	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8207341B2 (en)	2008-09-04	2012-06-26	Bristol-Myers Squibb Company	Process or synthesizing substituted isoquinolines
UY32099A (es) *	2008-09-11	2010-04-30	Enanta Pharm Inc	Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8563505B2 (en)	2008-09-29	2013-10-22	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8044087B2 (en)	2008-09-29	2011-10-25	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
AU2009324643B2 (en)	2008-12-10	2014-08-28	Achillion Pharmaceuticals, Inc.	New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8283310B2 (en)	2008-12-15	2012-10-09	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
LT2401272T (lt)	2009-02-27	2017-03-27	Janssen Pharmaceuticals, Inc.	Hcv makrociklinio slopiklio amorfinė druska
WO2010118078A1 (fr)	2009-04-08	2010-10-14	Idenix Pharmaceuticals, Inc.	Inhibiteurs macrocycliques de la sérine protéase
NZ596546A (en) *	2009-05-29	2012-12-21	Syngenta Participations Ag	Substituted quinazolines as fungicides
TW201117812A (en)	2009-08-05	2011-06-01	Idenix Pharmaceuticals Inc	Macrocyclic serine protease inhibitors
CA2822556A1 (fr)	2010-12-30	2012-07-05	Enanta Pharmaceuticals, Inc	Inhibiteurs macrocycliques de serine protease d'hepatite c
US8951964B2 (en)	2010-12-30	2015-02-10	Abbvie Inc.	Phenanthridine macrocyclic hepatitis C serine protease inhibitors
WO2012109398A1 (fr)	2011-02-10	2012-08-16	Idenix Pharmaceuticals, Inc.	Inhibiteurs macrocycliques de sérine protéase, compositions pharmaceutiques les contenant et leur utilisation pour le traitement des infections par le vhc
US8957203B2 (en)	2011-05-05	2015-02-17	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US10201584B1 (en)	2011-05-17	2019-02-12	Abbvie Inc.	Compositions and methods for treating HCV
US8691757B2 (en)	2011-06-15	2014-04-08	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
CA2858659A1 (fr)	2011-12-28	2013-07-04	Janssen R&D Ireland	Derives heterobicycliques en tant qu'inhibiteurs de vhc
NZ707115A (en) *	2012-10-15	2018-03-23	Albemarle Corp	Processes for the synthesis of 2-amino-4,6-dimethoxybenzamide and other benzamide compounds
BR112015007879A2 (pt)	2012-10-19	2017-07-04	Bristol Myers Squibb Co	inibidores do vírus da hepatite c
EP2914613B1 (fr)	2012-11-02	2017-11-22	Bristol-Myers Squibb Company	Inhibiteurs du virus de l'hépatite c
US9334279B2 (en)	2012-11-02	2016-05-10	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US9643999B2 (en)	2012-11-02	2017-05-09	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US9409943B2 (en)	2012-11-05	2016-08-09	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
EP2964664B1 (fr)	2013-03-07	2017-01-11	Bristol-Myers Squibb Company	Inhibiteurs du virus de l'hépatite c
US9006423B2 (en)	2013-03-15	2015-04-14	Achillion Pharmaceuticals Inc.	Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
US9085607B2 (en)	2013-03-15	2015-07-21	Achillion Pharmaceuticals, Inc.	ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
WO2015103490A1 (fr)	2014-01-03	2015-07-09	Abbvie, Inc.	Formes galéniques antivirales solides
EP3108879A1 (fr)	2015-06-25	2016-12-28	Cassiopea S.p.A.	Formulation à concentration élevée

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003053349A2 (fr) *	2001-12-20	2003-07-03	Bristol-Myers Squibb Company	Inhibiteurs de virus de l'hepatite c
WO2004037855A1 (fr) *	2002-10-25	2004-05-06	Boehringer Ingelheim International Gmbh	Peptides macrocycliques actifs contre le virus de l'hepatite c
WO2005028501A1 (fr) *	2003-09-22	2005-03-31	Boehringer Ingelheim International Gmbh	Peptides macrocycliques actifs contre le virus de l'hepatite c

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6323180B1 (en)	1998-08-10	2001-11-27	Boehringer Ingelheim (Canada) Ltd	Hepatitis C inhibitor tri-peptides
UA74546C2 (en) *	1999-04-06	2006-01-16	Boehringer Ingelheim Ca Ltd	Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
NZ575692A (en)	2002-04-11	2009-10-30	Vertex Pharma	Inhibitors of Serine Proteases, Particularly Hepatitis C Virus NS3-NS4 Protease
MY140680A (en)	2002-05-20	2010-01-15	Bristol Myers Squibb Co	Hepatitis c virus inhibitors
US20040180815A1 (en) *	2003-03-07	2004-09-16	Suanne Nakajima	Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
WO2004072243A2 (fr) *	2003-02-07	2004-08-26	Enanta Pharmaceuticals, Inc.	Inhibiteurs macrocycliques de la serine protease de l'hepatite c
EP1629000B1 (fr) *	2003-04-16	2009-02-18	Bristol-Myers Squibb Company	Peptide d'isoquinoleine macrocyclique inhibiteurs du virus de l'hepatite c
US7125845B2 (en) *	2003-07-03	2006-10-24	Enanta Pharmaceuticals, Inc.	Aza-peptide macrocyclic hepatitis C serine protease inhibitors
BRPI0506948B1 (pt) *	2004-01-30	2018-09-18	Medivir Ab	inibidores de serina protease ns-3 de hcv
PE20070211A1 (es) *	2005-07-29	2007-05-12	Medivir Ab	Compuestos macrociclicos como inhibidores del virus de hepatitis c
TWI393723B (zh) *	2005-07-29	2013-04-21	Tibotec Pharm Ltd	Ｃ型肝炎病毒之大環抑制劑（九）
US7700552B2 (en) *	2005-07-29	2010-04-20	Medivir Ab	Macrocyclic inhibitors of hepatitis C virus
TWI383980B (zh) *	2005-07-29	2013-02-01	Tibotec Pharm Ltd	Ｃ型肝炎病毒之大環抑制劑

2006
- 2006-07-26 PE PE2006000903A patent/PE20070343A1/es not_active Application Discontinuation
- 2006-07-28 HR HR20100209T patent/HRP20100209T1/hr unknown
- 2006-07-28 ES ES06764268T patent/ES2339702T3/es active Active
- 2006-07-28 PL PL06764268T patent/PL1912981T3/pl unknown
- 2006-07-28 UY UY29704A patent/UY29704A1/es unknown
- 2006-07-28 AU AU2006274866A patent/AU2006274866B2/en not_active Ceased
- 2006-07-28 AT AT06764268T patent/ATE455775T1/de active
- 2006-07-28 SI SI200630627T patent/SI1912981T1/sl unknown
- 2006-07-28 ME MEP-2012-119A patent/ME01454B/me unknown
- 2006-07-28 PT PT06764268T patent/PT1912981E/pt unknown
- 2006-07-28 KR KR1020087004894A patent/KR101083631B1/ko not_active Expired - Fee Related
- 2006-07-28 GT GT200600343A patent/GT200600343A/es unknown
- 2006-07-28 TW TW095127585A patent/TWI387597B/zh not_active IP Right Cessation
- 2006-07-28 CA CA2617103A patent/CA2617103C/fr not_active Expired - Fee Related
- 2006-07-28 DE DE602006011905T patent/DE602006011905D1/de active Active
- 2006-07-28 MY MYPI20063670 patent/MY151026A/en unknown
- 2006-07-28 BR BRPI0614153-6A patent/BRPI0614153A2/pt not_active Application Discontinuation
- 2006-07-28 NZ NZ564540A patent/NZ564540A/en not_active IP Right Cessation
- 2006-07-28 WO PCT/EP2006/064822 patent/WO2007014927A2/fr not_active Ceased
- 2006-07-28 AP AP2008004306A patent/AP2585A/xx active
- 2006-07-28 US US11/995,900 patent/US7659245B2/en not_active Expired - Fee Related
- 2006-07-28 AR ARP060103303A patent/AR057702A1/es not_active Application Discontinuation
- 2006-07-28 JP JP2008523383A patent/JP5230418B2/ja not_active Expired - Fee Related
- 2006-07-28 DK DK06764268.6T patent/DK1912981T3/da active
- 2006-07-28 RS RSP-2010/0183A patent/RS51227B/sr unknown
- 2006-07-28 EA EA200800482A patent/EA014188B1/ru not_active IP Right Cessation
- 2006-07-28 EP EP06764268A patent/EP1912981B1/fr active Active
- 2006-07-29 SV SV2006002641A patent/SV2008002641A/es unknown
2007
- 2007-12-20 IL IL188320A patent/IL188320A/en not_active IP Right Cessation
2008
- 2008-02-29 NO NO20081075A patent/NO20081075L/no not_active Application Discontinuation
2010
- 2010-04-20 CY CY20101100355T patent/CY1110008T1/el unknown

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003053349A2 (fr) *	2001-12-20	2003-07-03	Bristol-Myers Squibb Company	Inhibiteurs de virus de l'hepatite c
WO2004037855A1 (fr) *	2002-10-25	2004-05-06	Boehringer Ingelheim International Gmbh	Peptides macrocycliques actifs contre le virus de l'hepatite c
WO2005028501A1 (fr) *	2003-09-22	2005-03-31	Boehringer Ingelheim International Gmbh	Peptides macrocycliques actifs contre le virus de l'hepatite c

Also Published As

Publication number	Publication date
JP2009502890A (ja)	2009-01-29
DK1912981T3 (da)	2010-05-25
TW200745116A (en)	2007-12-16
SV2008002641A (es)	2008-07-23
HK1116488A1 (en)	2008-12-24
EA014188B1 (ru)	2010-10-29
WO2007014927A3 (fr)	2007-11-29
RS51227B (sr)	2010-12-31
ATE455775T1 (de)	2010-02-15
NO20081075L (no)	2008-04-25
DE602006011905D1 (de)	2010-03-11
KR20080033475A (ko)	2008-04-16
WO2007014927A2 (fr)	2007-02-08
TWI387597B (zh)	2013-03-01
AU2006274866B2 (en)	2012-04-12
AR057702A1 (es)	2007-12-12
IL188320A (en)	2014-07-31
BRPI0614153A2 (pt)	2011-03-15
CA2617103A1 (fr)	2007-02-08
SI1912981T1 (sl)	2010-05-31
MY151026A (en)	2014-03-31
PL1912981T3 (pl)	2010-07-30
EP1912981A2 (fr)	2008-04-23
EP1912981B1 (fr)	2010-01-20
IL188320A0 (en)	2008-04-13
KR101083631B1 (ko)	2011-11-16
NZ564540A (en)	2010-03-26
PE20070343A1 (es)	2007-05-12
CY1110008T1 (el)	2015-01-14
US20090118312A1 (en)	2009-05-07
HRP20100209T1 (hr)	2010-05-31
JP5230418B2 (ja)	2013-07-10
EA200800482A1 (ru)	2008-06-30
GT200600343A (es)	2007-08-06
ES2339702T3 (es)	2010-05-24
ME01454B (me)	2014-04-20
UY29704A1 (es)	2007-05-31
AU2006274866A1 (en)	2007-02-08
CA2617103C (fr)	2015-01-06
US7659245B2 (en)	2010-02-09
PT1912981E (pt)	2010-04-16

Publication	Publication Date	Title
AP2585A (en)	2013-02-04	Macrocyclic inhibitors of hepatitis C virus
AP2473A (en)	2012-09-24	Macrocyclic inhibitors of hepatitis C virus
IL240244A0 (en)	2015-09-24	Macrocyclic inhibitors of hepatitis c virus
SI1912997T1 (sl)	2012-02-29	Makrociklični inhibitorji virusa hepatitis C
SI1919898T1 (sl)	2011-05-31	Makrociklični inhibitorji virusa hepatitisa C
PL1919904T3 (pl)	2014-06-30	Makrocykliczne inhibitory wirusa zapalenia wątroby typu C
IL188281A0 (en)	2008-04-13	Macrocyclic inhibitors of hepatitis c virus
SI1919899T1 (sl)	2011-05-31	Makrociklični inhibitorji virusa hepatitisa C
SI1913015T1 (sl)	2014-05-30	Makrociklični inhibitorji virusa Hepatitis C
IL221361A0 (en)	2012-09-24	Novel macrocyclic inhibitors of hepatitis c virus replication
ZA200800859B (en)	2009-06-24	Macrocyclic inhibitors of hepatitis C virus
ZA200800860B (en)	2009-06-24	Macrocyclic inhibitors of hepatitis C virus
ZA200800856B (en)	2009-06-24	Macrocyclic inhibitors of hepatitis C virus
ZA200800715B (en)	2010-02-24	Novel macrocyclic inhibitors of hepatitis C virus replication